文献速递乳腺癌支持与姑息治疗

二甲双胍对比安慰剂对加拿大癌症试验组MA.32研究中新发原发癌的影响:一项早期乳腺癌III期随机双盲试验的二次分析

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.
PubMed 文献 · J Clin Oncol · 2023-09-11

MA.32试验纳入3649例无糖尿病的高危早期乳腺癌患者,随机接受二甲双胍850mg每日两次或安慰剂每日两次共5年。二甲双胍未降低新发浸润癌风险(HR 1.25,95%CI 0.94-1.68,P=0.13),对侧浸润性乳腺癌(HR 1.29)和非乳腺癌新发原发癌(HR 1.24)风险均无显著影响。

要点

  • 二甲双胍未降低无糖尿病早期乳腺癌患者新发浸润癌风险(HR 1.25,95%CI 0.94-1.68)
  • 对侧浸润性乳腺癌风险无显著差异(HR 1.29,95%CI 0.72-2.27)
  • 非乳腺癌新发原发癌风险无显著差异(HR 1.24,95%CI 0.88-1.74)

核心结论

  • 在无糖尿病的乳腺癌患者中,二甲双胍未降低新发癌症发生风险。

研究设计与样本

  • MA.32为III期随机双盲试验,2010至2013年纳入3649例无糖尿病、小于75岁的高危T1-3、N0-3、M0乳腺癌患者(任何ER、PR、HER2状态)。
  • 患者随机接受二甲双胍850mg口服每日两次或安慰剂每日两次,共5年。
  • 新发原发浸润癌(同侧乳腺以外)作为首次事件被识别,采用竞争风险方法描述事件时间,并使用校正年龄、BMI、吸烟和饮酒的两侧似然比检验比较两组。

主要发现

  • 共184例患者发生新发浸润癌:二甲双胍组102例,安慰剂组82例,HR 1.25;95%CI 0.94-1.68;P=0.13。
  • 对侧浸润性乳腺癌48例(二甲双胍组27例 vs 安慰剂组21例),HR 1.29;95%CI 0.72-2.27;P=0.40。
  • 非乳腺癌新发原发癌136例(二甲双胍组75例 vs 安慰剂组61例),HR 1.24;95%CI 0.88-1.74;P=0.21。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 randomized adjuvant breast cancer trial, metformin (v placebo) did not affect invasive disease-free or overall survival. Here, we report metformin effects on the risk of new cancer. Between 2010 and 2013, 3,649 patients with breast cancer younger than 75 years without diabetes with high-risk T1-3, N0-3 M0 breast cancer (any estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2) were randomly assigned to metformin 850 mg orally twice a day or placebo twice a day for 5 years. New primary invasive cancers (outside the ipsilateral breast) developing as a first event were identified. Time to events was described by the competing risks method; two-sided likelihood ratio tests adjusting for age, BMI, smoking, and alcohol intake were used to compare metformin versus placebo arms. A total of 184 patients developed new invasive cancers: 102 metformin and 82 placebo, hazard ratio (HR), 1.25; 95% CI, 0.94 to 1.68; P = .13. These included 48 contralateral invasive breast cancers (27 metformin v 21 placebo), HR, 1.29; 95% CI, 0.72 to 2.27; P = .40 and 136 new nonbreast primary cancers (75 metformin v 61 placebo), HR, 1.24; 95% CI, 0.88 to 1.74; P = .21. Metformin did not reduce the risk of new cancer development in these nondiabetic patients with breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Goodwin PJ, Chen BE, Gelmon KA, et al. Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. J Clin Oncol. 2023. PMID: 37695982. doi:10.1200/JCO.23.00296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。